Supplemental triglyceride-lowering therapy may lower CVD risk in statin-treated patients with diabetic dyslipidemia, study finds
The rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes was 27% lower in participants with dyslipidemia randomized to fenofibrate than among those randomized to placebo.
ACP recommended that clinicians prescribe metformin for type 2 diabetes when pharmacologic therapy is needed to improve glycemic control in a strong recommendation based on moderate-quality evidence.
The position statement recommends that physicians consider assessing cognitive capacities and symptoms of diabetes distress, depression, anxiety, and disordered eating at the initial visit and at periodic intervals.
Our findings also highlight the need for early intervention aimed to reduce risk factors for overweight or obesity in type 2 diabetic individuals to preserve their brain structure and cognitive function,”
The study included patients 65 years of age and older with type 1 or type 2 diabetes admitted to a Veterans Affairs nursing home, and they were categorized by baseline HbA1c (6.0% to 6.9%, 7.0% to 7.9%, 8.0% to 8.9%, and 9.0% or higher).
The intervention for Medicare beneficiaries with prediabetes includes at least 16 weekly hour-long sessions over months 1 to 6 and at least 6 monthly maintenance sessions over months 6 to 12.
Continuous glucose monitoring associated with lower HbA1c in type 1 diabetes treated with insulin injection
An editorial accompanying the two trials of continuous glucose monitoring stressed that the physicians involved had extensive experience with the technology and noted that the necessary changes in lifestyle and insulin dosing can be variable and
The blood glucose awareness training involved three 2.5-hour group sessions over 4 weeks plus 2 online modules to be done between group meetings.
Non-endocrinologist clinicians who electronically ordered glargine at a dose of 0.5 units/kg or greater incurred a warning screen, which advised either lowering the dose or contacting the diabetes consult service for approval.
These results clearly highlight the need to respect existing recommendations for dose reduction of sulphonylureas when initiating treatment with DPP-4 inhibitors, and the urgency to determine the efficacy of this